Original Date: June 4-5, 2016
Small intestine bacterial overgrowth (SIBO) is a chronic bacterial colonization of the small intestine. These bacteria normally live in the gastrointestinal tract, however, in SIBO they have overgrown in a location not meant for so many bacteria. The bacteria interfere with our normal digestion and absorption of food and are associated with damage to the lining or membrane of the small intestine. These mechanisms in turn lead to myriad other disorders—gastrointestinal, systemic, and neurological.
The 3rd Annual SIBO Symposium features the nation’s leading experts on the topic to present an evidence-based educational program on managing small intestine bacterial overgrowth. For more information, visit www.sibosymposium.com
Presentations include:
- Top 10 Highlights of SIBO 2014 & 2015
- Pharmacologic Treatment of SIBO
- Biofilm Degrading Agents As Synergists; Atrantil in Treating SIBO; Methods for Patient Research
- LDN – Updates in Rx
- Underlying Causes – PPIs and Hypochlorohydria
- Are Generic Formulations Really Bioequivalent to Branded Drugs? The Case for Rifaximin
- Dysbiosis in Syndromes and Diseases
- Phased Diet & Herbal Antimicrobials
- GI Manifestations and Pattern Recognition in Lyme and Common Tick-Borne Illnesses
- The Intersection of SIBO and IBD
- Rifaximin for the Treatment of SIBO: A Systematic Review and Meta-analysis
- Updated Diet Guidelines
- Adhesions – The "Missing Link" for Unresolved SIBO?
- Clinical Pearls Presentations and Open Forum
3.0 Pharmacology and 9.5 General (12.5 CEUs) for NDs approved by OBNM